MA54464A - Anticorps humanisé anti-récepteur de l'igf-i - Google Patents

Anticorps humanisé anti-récepteur de l'igf-i

Info

Publication number
MA54464A
MA54464A MA054464A MA54464A MA54464A MA 54464 A MA54464 A MA 54464A MA 054464 A MA054464 A MA 054464A MA 54464 A MA54464 A MA 54464A MA 54464 A MA54464 A MA 54464A
Authority
MA
Morocco
Prior art keywords
igf
humanized anti
receptor antibody
antibody
receptor
Prior art date
Application number
MA054464A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Hirofumi Higuchi
Daisuke Ishikawa
Hirotsugu Kato
Naoko Namiki
Masayo Ohori
Kenichiro Takagi
Tomoyo Takeo
Akira Tanokura
Satoshi Yamamura
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA54464A publication Critical patent/MA54464A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA054464A 2018-12-03 2019-12-02 Anticorps humanisé anti-récepteur de l'igf-i MA54464A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018226669 2018-12-03

Publications (1)

Publication Number Publication Date
MA54464A true MA54464A (fr) 2021-10-20

Family

ID=70974206

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054464A MA54464A (fr) 2018-12-03 2019-12-02 Anticorps humanisé anti-récepteur de l'igf-i

Country Status (19)

Country Link
US (1) US20220033485A1 (fr)
EP (1) EP3895732A4 (fr)
JP (2) JP7246409B2 (fr)
KR (1) KR20210088625A (fr)
CN (1) CN113286612A (fr)
AR (1) AR117673A1 (fr)
AU (1) AU2019393487A1 (fr)
BR (1) BR112021010479A2 (fr)
CA (1) CA3120740A1 (fr)
CL (1) CL2021001446A1 (fr)
CO (1) CO2021007229A2 (fr)
IL (1) IL283099A (fr)
MA (1) MA54464A (fr)
MX (1) MX2021006495A (fr)
PH (1) PH12021551210A1 (fr)
SG (1) SG11202105714UA (fr)
TW (1) TW202039559A (fr)
WO (1) WO2020116398A1 (fr)
ZA (1) ZA202103350B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021246413A1 (fr) * 2020-06-02 2021-12-09

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399483B1 (fr) * 2001-01-05 2010-04-14 Pfizer Inc. Anticorps anti-recepteur du facteur de croissance insulinoide i
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
BRPI0910338A2 (pt) 2008-04-03 2020-08-18 F. Hoffmann-La Roche Ag uso de variantes peguiladas de igf-i para o tratamento de distúbios neuromusculares
JP6096267B1 (ja) 2015-12-09 2017-03-15 上銀科技股▲分▼有限公司 ボールねじに用いる防塵ユニット
CA3056573A1 (fr) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anticorps anti-recepteur igf-i

Also Published As

Publication number Publication date
JP2023011808A (ja) 2023-01-24
CA3120740A1 (fr) 2020-06-11
EP3895732A4 (fr) 2022-09-14
JPWO2020116398A1 (ja) 2021-09-30
TW202039559A (zh) 2020-11-01
EP3895732A1 (fr) 2021-10-20
AR117673A1 (es) 2021-08-25
PH12021551210A1 (en) 2021-11-08
CO2021007229A2 (es) 2021-08-19
BR112021010479A2 (pt) 2021-11-16
CL2021001446A1 (es) 2022-01-14
MX2021006495A (es) 2021-07-06
SG11202105714UA (en) 2021-06-29
WO2020116398A1 (fr) 2020-06-11
CN113286612A (zh) 2021-08-20
US20220033485A1 (en) 2022-02-03
AU2019393487A1 (en) 2021-06-03
ZA202103350B (en) 2022-08-31
JP7246409B2 (ja) 2023-03-27
IL283099A (en) 2021-06-30
KR20210088625A (ko) 2021-07-14

Similar Documents

Publication Publication Date Title
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA53434A (fr) Anticorps anti-tigit
MA49990A (fr) Récepteurs de liaison à l'antigène améliorés
IL276396A (en) Chimeric antigen receptors against CD70
MA52884A (fr) Anticorps anti-il-11
MA51428A (fr) Récepteur d'antigène chimérique multivalent
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA52212A (fr) Anticorps multivalent
MA52366A (fr) Anticorps anti-tl1a optimisés
MA51903A (fr) Formulations d'anticorps b7-h4
IL270971A (en) Antibody against the 1-IGF receptor
DK3806903T3 (da) Cd79a kimæriske antigenreceptorer
MA52152A (fr) Anticorps
MA53218A (fr) Antagonistes de l'intégrine
MA54052A (fr) Formulation d'anticorps
ZA202205226B (en) Ri-labeled humanized antibody
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
MA54139A (fr) Formulation d'anticorps
IL285587A (en) Chimeric antigen receptors respond to hypoxia
MA56466A (fr) Anticorps anti-epha4
MA55705A (fr) Anticorps bispécifiques
MA49259A (fr) Anticorps thérapeutiques à base d'hexamères d'igg mutées
IL287310A (en) Antibodies against 4g7-derived bacterial chemoreceptors
ZA202102879B (en) Anti-human fn14 antibody
MA54464A (fr) Anticorps humanisé anti-récepteur de l'igf-i